-logo.jpg "Sartorius logo")
Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.
Read More…
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+49-551-3080
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees8,500
Next Earnings DateN/A
OptionableNot Optionable
Sartorius (FRA:SRT3) Frequently Asked Questions
What is Sartorius' stock symbol?
Sartorius trades on the FRA under the ticker symbol "SRT3."
What price target have analysts set for SRT3?
9 Wall Street analysts have issued 12-month price targets for Sartorius' shares. Their predictions range from €97.50 to €184.00. On average, they expect Sartorius' share price to reach €147.61 in the next year. This suggests that the stock has a possible downside of 12.1%. View Analyst Price Targets for Sartorius.
What is the consensus analysts' recommendation for Sartorius?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sartorius in the last year. There are currently 5 sell ratings and 4 hold ratings for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for Sartorius.
Has Sartorius been receiving favorable news coverage?
News articles about SRT3 stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sartorius earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Sartorius.
Who are some of Sartorius' key competitors?
What other stocks do shareholders of Sartorius own?
Who are Sartorius' key executives?
Sartorius' management team includes the folowing people:
- Dr. Joachim Kreuzburg, Chairman of Exec. Board & CEO (Age 54)
- Mr. Rainer Lehmann, CFO & Member of Exec. Board and Head of Fin., Information Technology & Bus. Process (Age 43)
- Ms. Petra Kirchhoff, Head of Corp. Communications & Investor Relations and Member of Supervisory Board (Age 50)
- Mr. Gerry Mackay, Head of Lab Products & Services Division & Member of Exec. Board (Age 56)
- Dr. René Fáber, Head of Bioprocess Solutions Division & Member of Exec. Board (Age 43)
What is Sartorius' stock price today?
One share of SRT3 stock can currently be purchased for approximately €167.90.
What is Sartorius' official website?
How can I contact Sartorius?
Sartorius' mailing address is Weender Landstrasse 94-108, GOETTINGEN, 37075, Germany. The company can be reached via phone at +49-551-3080.
MarketBeat Community Rating for Sartorius (FRA SRT3)
MarketBeat's community ratings are surveys of what our community members think about Sartorius and other stocks. Vote "Outperform" if you believe SRT3 will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRT3 will underperform the S&P 500 over the long term. You may vote once every thirty days.
